Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.

Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 8, ...

GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. This article originally appeared on Medical News Today ...

The Food and Drug Administration has officially approved Breo Ellipta, a much-anticipated new treatment for chronic obstructive pulmonary disease. The inhaled drug was developed by GlaxoSmithKline ...

The global chronic obstructive pulmonary disease (COPD) drugs market is poised to grow by USD 3.52 billion during 2019-2023, according to Technavio ...

Nearly 20% of US patients with chronic obstructive pulmonary disease skip or delay doses due to high monthly out-of-pocket costs for medication.

Chronic obstructive pulmonary disease (COPD) is a leading cause of death and of emergency hospital admissions worldwide. 1, 2 The efficacy of COPD drugs in reducing exacerbations and hospital ...

This COPD drugs industry research report provides an in-depth analysis of the major drivers, upcoming trends, and challenges that will impact market growth over the forecast period.

It is not intended to treat another form of COPD, which involves primary emphysema. The medication is marketed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.

The newly approved Stiolto Respimat combines two drugs to better open airways in patients with chronic obstructive pulmonary disease. The U.S. Food and Drug Administration (FDA) has approved a new ...